Financial Results
Q1/2025 Results
Strong start to 2025 – #FutureFresenius REJUVENATE phase kicked-off with excellent momentum
Q1/2025: Strong top line and excellent EPS growth, outlook confirmed
- Group revenue1 at €5.63 billion with strong organic growth of 7%1,2 driven by consistent delivery of Fresenius Kabi and a strong performance at Fresenius Helios.
- Group EBIT1 at €654 million, increase of 4%3 in constant currency on the back of strong operating performance at Kabi; absence of energy relief payments weighing on Helios Germany; Group EBIT margin1 of 11.6%.
- Net income1,4 grew by an excellent 12%3 in constant currency to €416 million significantly outpacing revenue growth.
- EPS1,4 rose by excellent 12%3 in constant currency to €0.74 resulting from broad based operational strength and lower interest expenses.
- Operating cash flow from continuing operations of €74 million significantly improved year-on-year driven by operating development and increased focus on cash generation.
- Leverage ratio within target corridor: Net debt/EBITDA ratio at 3.0x1,5 showing 80 bps improvement in the last twelve months.
- #FutureFresenius REJUVENATE phase: Pivotal milestone delivered with the reduction of participation in Fresenius Medical Care stake enhancing strategic flexibility while setting basis for long-term profitable growth.
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation.
3 Growth rate adjusted for Argentina hyperinflation.
4 Excluding Fresenius Medical Care
5 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend, net debt adjusted for the valuation effect of the equity-neutral exchangeable bond.
Selected Key Figures Q1/2025
GROUP REVENUE 1
€ 5631 m
+ 7% 2
Q1/24: €5,283 m
GROUP EBIT 1
€ 654 m
+4% 3
Q1/24: €631 m
NET INCOME 1, 4
€ 416 m
+12% 3
Q1/24: €371 m
EPS 1, 4
€ 0.74
+12% 3
Q1/24: €0.66
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation
4 Excluding Fresenius Medical Care
Revenue by business segment
| € in millions | Q1/25 | Q1/24 | Growth at actual rates | Growth at constant rates | Organic growth1 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 2,146 | 2,051 | 5% | 5% | 6%1 | -1% | 38% |
Fresenius Helios | 3,394 | 3,154 | 8% | 8% | 8% | 0% | 60% |
Total | 5,631 | 5,283 | 7% | 7% | 7% | 0% | 100%2 |
-
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Remaining 2% Corporate/Other revenue
Before special items